 |
市场调查报告书
商品编码
1738728
全球癌症疫苗市场规模：按疫苗类型、按癌症类型、按技术、按最终用户、按地区和预测Global Cancer Vaccine Market Size By Type of Vaccine, By Type of Cancer, By Technology, By End User, By Geographic Scope And Forecast |
||||||
癌症疫苗市场规模及预测
预计 2024 年癌症疫苗市场规模将达到 100.4 亿美元，到 2032 年将达到 174.9 亿美元，2026 年至 2032 年的复合年增长率为 7.93%。
癌症疫苗是一种免疫疗法，旨在增强免疫系统识别和对抗癌细胞的能力。这些疫苗针对癌细胞上的特定抗原，引发免疫反应，清除恶性肿瘤细胞，同时保留健康组织，从而防止癌症形成或復发。癌症疫苗既可以预防特定恶性肿瘤，也可以治疗现有癌症，透过增强免疫监测和对癌细胞的反应来治疗。该领域的研究重点是根据患者的个别特征开发个人化疫苗，并利用新型免疫技术来提高疫苗疗效。
癌症疫苗既可用于预防癌症，也可用于治疗癌症。预防性癌症疫苗，例如针对子宫颈癌的人类乳突病毒 (HPV) 疫苗，旨在透过靶向已知致癌的感染性微生物来预防癌症的发生。另一方面，治疗性癌症疫苗旨在透过激活免疫系统识别并摧毁癌细胞来治疗活跃的癌症。这些疫苗可以单独使用，也可以与其他治疗方法（例如手术、化疗或标靶治疗）合併使用，以增强人体对肿瘤的免疫反应。目前正在进行的研究正在探索新的疫苗接种目标、给药策略和联合治疗，以改善癌症患者的预后。
癌症疫苗有可能成为根据个人基因图谱和肿瘤特征量身定制的个人化医疗技术的关键组成部分。免疫疗法和生物标记研究的进展有望带来更有效的疫苗，这些疫苗可以靶向更广泛的恶性肿瘤并诱导持久的免疫反应。奈米颗粒和病毒载体是两种疫苗递送系统的创新，它们可以提高疗效并减少副作用。此外，人工智慧和基因组分析的应用可以透过预测患者预后并提案合适的治疗方法组合来改善疫苗研发。随着研究的进展，癌症疫苗有望在癌症治疗模式转向更有针对性、毒性更低且具有潜在治癒力的药物转变中发挥关键作用。
癌症疫苗市场动态
影响癌症疫苗市场的关键市场动态是：
关键市场驱动因素
癌症发生率不断上升：随着全球癌症发生率的上升，对有效预防和治疗方案的需求也日益增长，例如针对特定癌症类型的疫苗。疫苗具有降低癌症风险和復发的潜力，对医疗保健专业人士和寻求预防性治疗方法的人具有吸引力。
免疫疗法的进展：免疫疗法在癌症治疗中产生的革命性影响，促使人们研究癌症疫苗作为一种强大的免疫疗法。疫苗透过激活免疫系统识别并杀死癌细胞，有助于制定个人化治疗方法，并为对常规药物无效的患者带来新的希望。
政府倡议与资金筹措：政府资助的倡议与资金正在帮助加速癌症疫苗的研发。监管激励措施、津贴以及官民合作关係为临床试验、监管核准和市场准入提供支援。这些计画促进疫苗创新和相关人员合作，以解决癌症治疗领域尚未满足的医疗需求。
主要问题
复杂的癌症生物学：癌症生物学非常复杂，包含多种亚型和基因异常，因此很难找到通用的疫苗标靶。肿瘤异质性和免疫逃脱机制使疫苗的配製和疗效面临挑战，因此精准的抗原选择和个人化治疗对于改善治疗效果至关重要。
临床试验设计与检验：确定癌症疫苗的目标、病患选择和临床试验设计都极具挑战性。确定疫苗效力通常需要长期追踪、复杂的生物标记分析以及严格的监管审查。此外，由于免疫反应因患者而异，因此需要进行大规模、多样化的测试队列来验证疫苗效力。
市场准入与商业化：癌症疫苗进入市场需要与监管机构谈判、获得报销核准并克服定价挑战。高昂的开发成本、来自现有企业的竞争以及医疗专业人员和患者对疫苗接受度的不确定性阻碍了商业性成功。策略联盟和游说活动是克服这些障碍并确保疫苗广泛可及的关键。
主要趋势
个人化医疗方法：根据患者个别情况客製化癌症疫苗的趋势日益增长。基因序列测定和生物标记辨识技术的进步使得针对患者肿瘤中发现的特定突变和新抗原的疫苗研发成为可能。这种个人化方法透过最大限度地提高针对肿瘤特异性抗原的免疫反应来提高疫苗效力。
联合疗法：人们越来越关注将癌症疫苗与其他免疫疗法（例如查核点抑制剂和细胞激素疗法）合併使用，以改善治疗效果。疫苗和免疫调节药物的协同效应旨在增强免疫激活，克服肿瘤微环境中的免疫抑制，并改善患者对治疗的反应。
疫苗递送技术的创新：提升疫苗效力和效能。奈米颗粒、病毒载体和基于树突状细胞的疫苗接种技术能够实现标靶抗原递送、扩大呈现抗原并增强免疫活化。这些改进旨在提高疫苗效力，同时最大限度地减少副作用，从而加速下一代癌症疫苗的研发。
癌症疫苗市场区域分析
以下是癌症疫苗市场更详细的区域分析：
北美洲
据Verified Market Research分析师称，北美占据了癌症疫苗市场的最大市场占有率。该地区拥有强大的研发能力，并拥有雄厚的资金和基础设施。北美的大型製药企业和研究机构正在推动癌症疫苗技术的创新，加速临床试验，并将新药推向市场。
北美的监管体係有利于加速疫苗研发和批准。美国药物管理局（FDA）等机构简化了包括疫苗在内的生技药品製剂的监管途径，使其比其他地区更快进入市场。这种高效的监管模式鼓励了投资，并创造了竞争环境，使企业能够快速将新型癌症疫苗带给患者。
北美稳健的医疗环境和高昂的医疗支出正在推动癌症疫苗等新型疗法的普及。该地区完善的医疗基础设施为患者提供了获得尖端治疗方法的机会，为新型免疫接种的商业化和推广创造了良好的环境。学术界、产业界和医疗机构之间的合作关係也促进了知识交流和创新免疫疗法的应用，巩固了北美在全球癌症疫苗市场的领导地位。
亚太地区
亚太地区的癌症疫苗市场蓬勃发展。该地区人口快速成长，癌症发生率不断上升，推动了对新型治疗方法的需求，其中包括癌症疫苗。由于人口老化、生活方式改变和环境因素，中国、印度和日本等国家的癌症发生率不断上升，这推动了癌症疫苗市场的发展。
亚太地区正受惠于医疗基础设施和研究能力投资的不断增加。该地区的政府和私人企业正在大力投资医疗保健系统和生物製药研发。这些投资推动了癌症疫苗技术、临床试验和监管核准的改进，促进了市场的快速扩张。
亚太地区癌症疫苗的普及得益于医疗法规的不断变化，以及医护人员和患者对免疫疗法和个人化医疗益处的日益了解。该地区人口结构和基因特征的多样性要求采用个人化的治疗方法，这与强调根据患者俱体特征标靶治疗的个人化医疗趋势相一致。
癌症疫苗市场区隔分析
癌症疫苗市场根据疫苗类型、癌症类型、技术、最终用户和地区进行细分。
癌症疫苗市场（以疫苗类型）
- 预防性疫苗
- 治疗性疫苗
根据疫苗类型，市场分为预防性疫苗和治疗性疫苗。治疗性癌症疫苗目前占据市场主导地位，因为它们旨在治疗现有癌症病例。这些疫苗能够激活免疫系统识别并靶向癌细胞，从而阻止疾病发展并改善患者预后。虽然像人类乳突病毒(HPV)疫苗这样的预防性疫苗在降低癌症发生率方面发挥着重要作用，但治疗性疫苗则瞄准当前的医疗需求，并展现出透过个人化免疫治疗技术改善癌症治疗方案的巨大潜力。
癌症疫苗市场（按癌症类型划分）
- 子宫颈癌
- 摄护腺癌
- 肺癌
- 乳癌
根据癌症类型，市场分为子宫颈癌、前列腺癌、肺癌和乳癌，其中乳癌乳癌，因为其在世界范围内发病率高，并且正在积极研究针对特定乳癌抗原的疫苗接种等治疗方法，以改善治疗效果和存活率。
癌症疫苗市场（按技术）
- 胜肽类疫苗
- 树突细胞疫苗
- 基于载体的疫苗
- DNA/RNA疫苗
根据技术，市场细分为胜肽类疫苗、树突细胞疫苗、载体疫苗和DNA/RNA疫苗。肽类疫苗目前在癌症疫苗市场占据主导地位，因为它们能够精准靶向肿瘤抗原，从而增强针对癌细胞的免疫反应，并最大限度地减少脱靶效应，使其成为个人化免疫治疗的理想选择。
癌症疫苗市场（按最终用户划分）
- 医院和诊所
- 癌症研究所
- 生物製药公司
- 政府和非营利组织
根据最终用户，市场分为医院诊所、癌症研究机构、生物製药公司、政府机构和非营利组织。医院诊所占据主导地位，因为它们提供全面的医疗保健服务和癌症相关需求的管理，直接为患者提供疫苗接种、癌症治疗和诊断服务。
癌症疫苗市场（按地区）
- 北美洲
- 欧洲
- 亚太地区
- 中东
- 拉丁美洲
根据区域分析，市场分为四个区域：北美、欧洲、亚太地区、拉丁美洲和中东及非洲。北美在全球癌症疫苗产业占据主导地位有几个关键原因。该地区受益于现代化的医疗基础设施、大量的研发支出以及强有力的法规环境，有助于快速核准和推出新型治疗方法。北美大型製药企业正在利用其广泛的临床实验室网络和与顶尖研究机构的合作关係，率先开发新型癌症疫苗。此外，高昂的医疗支出和庞大的患者群体正在推动癌症疫苗的广泛采用，巩固了北美在这一重要医疗领域的领导地位。
主要参与企业
- 全球癌症疫苗市场研究报告提供了针对全球市场的宝贵见解。市场主要企业包括葛兰素史克、默克公司、辉瑞、赛诺菲巴斯德、CSL有限公司、Astellas来製药和印度血清实验室。
我们的市场分析还包括针对这些关键公司的专门部分，我们的专家将在其中提供有关其财务报表、产品基准和 SWOT 分析的见解，而竞争格局部分还包括上述全球竞争对手的关键发展策略、市场占有率和市场排名分析。
- 癌症疫苗市场的最新趋势：
- 2023年9月，尼日利亚联邦政府即将推出人类乳突病毒（HPV）疫苗，以挽救该国数百人的生命，并减少该国少女的子宫颈癌病例数。
- 继2022年1月推出针对新冠病毒的mRNA疫苗后，生技公司Moderna和BIoTech宣布正在研发癌症疫苗。英国癌症研究中心（CRUK）高级研究资讯经理Sam Godfrey谈到了mRNA癌症疫苗的研发进展。
- 2023 年 8 月，卫生部长史蒂芬唐纳利 (Stephen Donnelly) 宣布扩大劳拉布伦南 HPV（人类乳突病毒）疫苗补种计划，将所有 22 岁以下的男孩纳入其中。
目录
第一章 引言
- 市场定义
- 市场区隔
- 调查方法
第二章执行摘要
- 主要发现
- 市场概览
- 市集亮点
第三章市场概述
- 市场规模和成长潜力
- 市场趋势
- 市场驱动因素
- 市场限制
- 市场机会
- 波特五力分析
第四章 癌症疫苗市场（依疫苗类型）
- 预防性疫苗
- 治疗性疫苗
第五章 癌症疫苗市场（依癌症类型）
- 子宫颈癌
- 摄护腺癌
- 肺癌
- 乳癌
- 其他癌症
第六章 癌症疫苗市场（依技术）
- 胜肽类疫苗
- 树突细胞疫苗
- 基于载体的疫苗
- DNA/RNA疫苗
第七章 癌症疫苗市场（依最终用户）
- 医院和诊所
- 癌症研究所
- 生物製药公司
- 政府和非营利组织
第八章区域分析
- 北美洲
- 美国
- 加拿大
- 墨西哥
- 欧洲
- 英国
- 德国
- 法国
- 义大利
- 亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 拉丁美洲
- 巴西
- 阿根廷
- 智利
- 中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿拉伯聯合大公国
第九章市场动态
- 市场驱动因素
- 市场限制
- 市场机会
- COVID-19 市场影响
第十章 竞争格局
- 主要企业
- 市场占有率分析
第十一章 公司简介
- ABB（瑞士）
- 西门子股份公司（德国）
- 瓦锡兰（芬兰）
- 康斯伯格集团（挪威）
- Leclanche SA（瑞士）
- 通用动力电船公司（美国）
- Corvus Energy（挪威）
第十二章 市场展望市场展望与机会
- 新兴技术
- 未来市场趋势
- 投资机会
第十三章 附录
- 简称列表
- 来源和参考文献
Cancer Vaccine Market Size and Forecast
Cancer vaccine market size was valued at USD 10.04 Billion in 2024 and is projected to reach USD 17.49 Billion by 2032, growing at a CAGR of 7.93% from 2026 to 2032.
Cancer vaccines are immunotherapy treatments that boost the immune system to recognise and fight cancer cells. These vaccines attempt to prevent cancer formation or recurrence by targeting specific antigens found on cancer cells eliciting an immune response that eliminates malignant cells while preserving healthy tissue. Cancer vaccines can be preventive meaning they are designed to prevent specific malignancies or therapeutic meaning they are used to treat existing cancer by improving immune surveillance and reaction against tumour cells. This field's research focuses on creating personalized vaccinations based on individual patient characteristics and enhancing efficacy using novel immunological techniques.
Cancer vaccines are used for both prevention and treatment in oncology. Prophylactic cancer vaccines such as human papillomavirus (HPV) vaccinations for cervical cancer seek to prevent disease development by targeting infectious organisms known to cause cancer. Therapeutic cancer vaccines on the other hand are intended to treat active cancers by activating the immune system to recognise and destroy cancer cells. These vaccinations can be administered alone or in conjunction with other treatments like as surgery, chemotherapy, or targeted therapy to boost the body's immune response to tumors. Ongoing research investigates new vaccination targets, delivery strategies, and combination medicines to improve cancer patient outcomes.
Cancer vaccines have the potential to become key components of personalized medicine techniques that are tailored to individual genetic profiles and tumour features. Advances in immunotherapy and biomarker research are likely to result in more effective vaccinations that can target a broader range of malignancies and trigger long-lasting immune responses. Nanoparticles and viral vectors are two vaccine delivery system innovations that may improve efficacy while reducing side effects. Furthermore, using artificial intelligence and genomic analysis could improve vaccine development by predicting patient outcomes and suggesting appropriate therapy combinations. Cancer vaccines as research advances are poised to play a critical role in shifting cancer therapy paradigms towards more focused, less toxic, and potentially curative medicines.
Cancer Vaccine Market Dynamics
The key market dynamics that are shaping the cancer vaccine market include:
Key Market Drivers:
Growing Cancer Incidence: As worldwide cancer rates rise, so does the demand for effective preventative and treatment options such as vaccines that target specific cancer types. Vaccines have the potential to reduce cancer risk and recurrence which appeals to healthcare practitioners and people looking for proactive therapies.
Advancements in Immunotherapy: The revolutionary impact of immunotherapy on cancer treatment has prompted research into cancer vaccines as a powerful immunotherapeutic approach. Vaccines contribute to personalised treatment regimens by activating the immune system to recognise and kill cancer cells giving patients who have not responded to traditional medicines new hope.
Government Efforts and Financing: Government-supported efforts and financing help to accelerate cancer vaccine research and development. Regulatory incentives, grants, and public-private partnerships help with clinical trials, regulatory approvals, and market access. These programmes promote vaccine innovation and stakeholder collaboration to address unmet medical requirements in cancer care.
Key Challenges:
Cancer Biology Complex: Cancer biology is complex, with many subtypes and genetic abnormalities making it difficult to identify universal vaccine targets. Tumour heterogeneity and immune evasion mechanisms challenge vaccine formulation and efficacy necessitating precise antigen selection and personalised approaches to improve therapeutic outcomes.
Clinical Trial Design and Validation: Determining objectives, selecting patients, and designing trials for cancer vaccines are all challenging. Long-term follow-up periods, complicated biomarker analysis, and rigorous regulatory scrutiny are frequently required to determine vaccine efficacy. Furthermore, because immune responses vary between patients, large and diverse study cohorts are required to establish vaccine efficacy.
Market Access and Commercialization: Gaining market access for cancer vaccines entails negotiating regulatory procedures obtaining reimbursement approvals, and overcoming pricing difficulties. Commercial success is hampered by high development costs, competition from current medicines, and uncertainty about vaccine acceptance among healthcare professionals and patients. Strategic alliances and lobbying initiatives are critical for overcoming these barriers and ensuring widespread vaccine access.
Key Trends:
Personalised Medicine Approach: There is a growing trend of cancer vaccinations that are tailored to individual patient profiles. Advances in genomic sequencing and biomarker identification enable the development of vaccinations that target specific mutations or neoantigens found in a patient's tumour. This personalised method improves vaccine efficacy by maximising the immune response to tumor-specific antigens.
Combination Treatments: There is an increasing interest on combining cancer vaccines with other immunotherapies such as checkpoint inhibitors and cytokine treatments to improve treatment outcomes. The synergistic effects of vaccines and immunomodulatory drugs aim to increase immunological activation, overcome immune suppression in the tumour microenvironment, and improve patient response to therapy.
Innovations in Vaccination Delivery Technologies: They are increasing vaccine potency and efficacy. Nanoparticles, viral vectors, and dendritic cell-based vaccinations allow for targeted antigen delivery, extended antigen presentation, and increased immune activation. These improvements aim to improve vaccination efficacy while minimising side effects, hence speeding the development of next-generation cancer vaccines.
Cancer Vaccine Market Regional Analysis
Here is a more detailed regional analysis of the cancer vaccine market:
North America:
According to Verified Market Research analyst, the biggest market share for cancer vaccine market is held by the North America region. The region benefits from strong research and development capabilities which are supported by considerable financing and infrastructure. Leading pharmaceutical corporations and research institutions in North America are driving innovation in cancer vaccine technology accelerating clinical trials and bringing new medicines to market.
North America's regulatory systems are beneficial to expediting vaccine research and licensure. Agencies such as the FDA in the United States streamline regulatory routes for biologics including vaccines allowing for faster market access than other regions. This regulatory efficiency promotes investment and fosters a competitive environment in which businesses can quickly introduce novel cancer vaccines to patients.
North America's robust healthcare environment and high healthcare spending encourage widespread acceptance of novel therapeutics such as cancer vaccinations. The region's well-established healthcare infrastructure provides patients with access to cutting-edge therapies creating a favourable climate for the commercialization and adoption of new vaccinations. Collaborations among academia, industry, and healthcare providers also enhance knowledge exchange and the application of innovative immunotherapies, thereby consolidating North America's leadership in the worldwide cancer vaccine market.
Asia-Pacific:
Asia-Pacific is seeing a rapid growth in cancer vaccine market. The region's fast-growing population and rising cancer incidence fuel need for novel therapeutic alternatives including cancer vaccinations. Cancer incidences are increasing in countries such as China, India, and Japan as a result of ageing populations, lifestyle changes, and environmental factors driving the market for cancer vaccines.
The Asia-Pacific region benefits from increased investments in healthcare infrastructure and research capacity. Governments and commercial sectors across the area are investing heavily in healthcare systems and biopharmaceutical research and development. This investment promotes improvements in cancer vaccine technology, clinical trials, and regulatory approvals which contribute to the market's rapid expansion.
Adoption of cancer vaccines in Asia-Pacific is being driven by altering healthcare regulations and increased understanding among healthcare professionals and patients about the benefits of immunotherapy and personalised medicine. The region's various demographic and genetic profiles need specialised treatment approaches which are consistent with the personalised medicine trend of emphasising targeted therapies based on specific patient traits.
Cancer Vaccine Market: Segmentation Analysis
The cancer vaccine market is segmented on the basis of Type of Vaccine, Type of Cancer, Technology, End User and Geography.
Cancer Vaccine Market, By Type of Vaccine
- Preventive
- Therapeutic
Based on Type of Vaccine, the market is bifurcated into Preventive and Therapeutic. Therapeutic cancer vaccines presently dominate the market since they are designed to treat existing cancer cases. These vaccinations activate the immune system to recognise and target cancer cells which could halt disease development and improve patient outcomes. While preventive vaccines such as those for HPV are critical in lowering cancer incidence, therapeutic vaccines target current medical requirements and show great potential in improving cancer treatment options through personalised immunotherapy techniques.
Cancer Vaccine Market, By Type of Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Breast Cancer
Based on Type of Cancer, the market is bifurcated into Cervical Cancer, Prostate Cancer, Lung Cancer, Breast Cancer. Breast cancer dominates because of its large global prevalence and substantial research into therapeutic approaches such as vaccinations, that target specific breast cancer antigens to improve treatment outcomes and survival rates.
Cancer Vaccine Market, By Technology
- Peptide-based vaccines
- Dendritic cell vaccines
- Vector-based vaccines
- DNA/RNA-based vaccines
Based on Technology, the market is bifurcated into Peptide-based vaccines, Dendritic cell vaccines, Vector-based vaccines, DNA/RNA-based vaccines. Peptide-based vaccines now dominate the cancer vaccine landscape due to their precision in targeting tumour antigens which improves immune responses against cancer cells while minimising off-target effects making them ideal candidates for personalised immunotherapy techniques.
Cancer Vaccine Market, By End-User
- Hospitals and clinics
- Cancer Research Institutes
- Biopharmaceutical Companies
- Governmental and nonprofit organizations
Based on End-User, the market is bifurcated into Hospitals and clinics, Cancer Research Institutes, Biopharmaceutical Companies, Governmental and nonprofit organizations. Hospitals and clinics dominate because they provide direct immunisation, cancer treatment, and diagnosis services to patients offering comprehensive healthcare delivery and cancer-related needs management.
Cancer Vaccine Market, By Geography
- North America
- Europe
- Asia-Pacific
- Middle East
- Latin America
Based on regional analysis, The market is divided into four regions: North America, Europe, Asia Pacific, and Latin America, the Middle East, and Africa. Several major reasons contribute to North America's present dominance in the global cancer vaccine industry. The region benefits from modern healthcare infrastructure, major expenditures in R&D, and a strong regulatory environment that facilitates the prompt approval and marketing of novel treatments. Leading pharmaceutical corporations in North America are pioneering the development of novel cancer vaccines employing large clinical trial networks and collaborations with premier research institutes. Furthermore, high healthcare spending and a huge patient population help to drive wider adoption of cancer vaccinations cementing North America's leadership in this crucial healthcare sector.
Key Players
- The Global Cancer vaccine market study report will provide valuable insight with an emphasis on the global market. The major players in the market are GlaxoSmithKline, Merck & Co., Pfizer Inc., Sanofi Pasteur, CSL Limited, Astellas Pharma Inc., and Serum Institute of India.
Our market analysis also includes a part dedicated specifically to such significant firms, in which our experts provide insights into their financial statements, as well as product benchmarking and SWOT analysis. The competitive landscape section also contains important development strategies, market share, and market ranking analysis for the aforementioned competitors worldwide.
- Cancer Vaccine Market Recent Developments:
- In September 2023, The Federal Government of Nigeria's impending initiative to save hundreds of lives in the nation, the launch of (HPV) Human papillomavirus (HPV) vaccine, would reduce the number of cervical cancer cases in teenage girls in the country.
- In January 2022, following the release of mRNA vaccines against coronavirus, Moderna and Biotech, both biotech companies, announced that they are working on cancer vaccines. Sam Godfrey, senior research information manager at Cancer Research U.K. (CRUK), spoke on the push for development into mRNA cancer vaccines.
- In August 2023, The Minister for Health, Stephen Donnelly TD, announced that Laura Brennan's HPV (Human Papillomavirus) Vaccine Catch-Up Programme would be expanded. The programme will encompass all guys aged up to 22 years.
TABLE OF CONTENTS
1. Introduction
- Market Definition
- Market Segmentation
- Research Methodology
2. Executive Summary
- Key Findings
- Market Overview
- Market Highlights
3. Market Overview
- Market Size and Growth Potential
- Market Trends
- Market Drivers
- Market Restraints
- Market Opportunities
- Porter's Five Forces Analysis
4. Cancer Vaccine Market, By Type of Vaccine
- Preventive vaccinations
- Therapeutic vaccines
5. Cancer Vaccine Market, By Type of Cancer
- Cervical Cancer
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Other Forms of Cancer
6. Cancer Vaccine Market, By Technology
- Peptide-based vaccines
- Dendritic cell vaccines
- Vector-Based Vaccines
- DNA/RNA-Based Vaccines
7. Cancer Vaccine Market, By End User
- Hospitals and clinics
- Cancer Research Institutes
- Biopharmaceutical Companies
- Governmental and nonprofit organizations
8. Regional Analysis
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Asia-Pacific
- China
- Japan
- India
- Australia
- Latin America
- Brazil
- Argentina
- Chile
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
9. Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Impact of COVID-19 on the Market
10. Competitive Landscape
- Key Players
- Market Share Analysis
11. Company Profiles
- ABB (Switzerland)
- Siemens AG (Germany)
- Wartsila (Finland)
- Kongsberg Gruppen (Norway)
- Leclanche S.A. (Switzerland)
- General Dynamics Electric Boat (USA)
- Corvus Energy (Norway)
12. Market Outlook and Opportunities
- Emerging Technologies
- Future Market Trends
- Investment Opportunities
13. Appendix
- List of Abbreviations
- Sources and References
全球子宫颈癌疫苗市场规模：按产品类型、分销管道和地区分類的范围和预测全球新兴癌症疫苗市场规模（按类型、技术、适应症、区域范围和预测）全球肽类癌症疫苗市场规模（按类型、技术、应用、区域范围和预测）全球树突细胞癌症疫苗市场规模（按产品类型、最终用户、区域范围）预测（至 2025 年）全球癌症疫苗药物管道市场规模（依产品类型、最终用户、区域覆盖范围、预测）：
2025 年至 2033 年癌症疫苗市场报告（按类型、技术、适应症、最终用户和地区）全球mRNA癌症疫苗的临床试验趋势:各适应症市场趋势，开发优先顺序，市场机会(2025年)
新抗原癌症疫苗市场按新抗原类型、治疗标靶、疫苗平台、给药途径和最终用户划分－2025-2030 年全球预测癌症疫苗市场预测（按产品类型、配方、给药途径、开发阶段、适应症和最终用户）：2025 年至 2030 年
全球合成胜肽疫苗市场考察及预测（至2031年）